This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Best Value Stocks to Buy for May 15th
by Zacks Equity Research
CIXXF, JXN and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 15, 2024.
Cencora (COR) Q2 Earnings Top Estimates
by Zacks Equity Research
Cencora (COR) delivered earnings and revenue surprises of 4.11% and 2.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Best Value Stocks to Buy for February 12th
by Zacks Equity Research
XRX, EMBC and HMN made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 12, 2023.
Embecta Corp. (EMBC) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Embecta Corp. (EMBC) delivered earnings and revenue surprises of 35.56% and 4.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Premier, Inc. (PINC) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Premier, Inc. (PINC) delivered earnings and revenue surprises of 11.11% and 1.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Alignment Healthcare (ALHC) Moves 13.2% Higher: Will This Strength Last?
by Zacks Equity Research
Alignment Healthcare (ALHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Ideas feature highlights: Beacon Roofing Supply, Embecta and Western Midstream Partners
by Zacks Equity Research
Beacon Roofing Supply, Embecta and Western Midstream Partners have been highlighted in this Investment Ideas article.
Time to Buy These Intriguing Additions to Zacks Rank #1 (Strong Buy) List
by Shaun Pruitt
Several intriguing stocks were recently added to the Zacks Rank #1 (Strong Buy) list this week and shouldn't be overlooked as we round out what has been an exciting year for the stock market.
Embecta Corp. (EMBC) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Embecta Corp. (EMBC) delivered earnings and revenue surprises of 40.48% and 1.75%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
IceCure Medical Ltd. (ICCM) delivered earnings and revenue surprises of 0% and 65.58%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Embecta Corp. (EMBC) Q4 Earnings Expected to Decline
by Zacks Equity Research
Embecta Corp. (EMBC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of -55.56% and 5.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for October 16th
by Zacks Equity Research
CURO, ELUXY and EMBC have been added to the Zacks Rank #5 (Strong Sell) List on October 16, 2023.
Embecta Corp. (EMBC) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Embecta Corp. (EMBC) delivered earnings and revenue surprises of 50% and 4.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) Soars 6.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Avantor, Inc. (AVTR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Embecta Corp. (EMBC) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?
Embecta Corp. (EMBC) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Company News for May 15, 2023
by Zacks Equity Research
Companies in The News Are: IAG, SLF, NWSA, EMBC.
Embecta Corp. (EMBC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Embecta Corp. (EMBC) closed the most recent trading day at $28.52, moving -1.82% from the previous trading session.
Embecta (EMBC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
Embecta Corp. (EMBC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Embecta Corp. (EMBC) closed at $27.36 in the latest trading session, marking a -1.12% move from the prior day.
Embecta Corp. (EMBC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Embecta Corp. (EMBC) closed at $29.46, marking a +0.58% move from the previous day.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.